AD/PD Therapeutic Target Comparison Matrix

Migration, Crosslink

📗 Cite This Artifact

←

Home / Artifacts / AD/PD Therapeutic Target Comparison Matrix

📖

AD/PD Therapeutic Target Comparison Matrix

active

wiki page Created: 2026-04-02T07:18:57 By: crosslink-migration Quality: 50% ✓ SciDEX ID: wiki-therapeutics-ad-pd-target-compariso

📖 Wiki Page

therapeutic767 wordssynced 2026-04-02

AD/PD Therapeutic Target Comparison Matrix

Overview

flowchart TD AD_PD_Therapeutic_Target_Compa["AD/PD Therapeutic Target Comparison Matrix"] AD_PD_Therapeutic_Target_Compa["table"] AD_PD_Therapeutic_Target_Compa -->|"related to"| AD_PD_Therapeutic_Target_Compa style AD_PD_Therapeutic_Target_Compa fill:#81c784,stroke:#333,color:#000 AD_PD_Therapeutic_Target_Compa["class"] AD_PD_Therapeutic_Target_Compa -->|"related to"| AD_PD_Therapeutic_Target_Compa style AD_PD_Therapeutic_Target_Compa fill:#81c784,stroke:#333,color:#000 AD_PD_Therapeutic_Target_Compa["infobox"] AD_PD_Therapeutic_Target_Compa -->|"related to"| AD_PD_Therapeutic_Target_Compa style AD_PD_Therapeutic_Target_Compa fill:#81c784,stroke:#333,color:#000 style AD_PD_Therapeutic_Target_Compa fill:#4fc3f7,stroke:#333,color:#000

...

AD/PD Therapeutic Target Comparison Matrix

Overview

Mermaid diagram (expand to render)

<table class="infobox infobox-therapeutic">
<tr>
<th class="infobox-header" colspan="2">AD/PD Therapeutic Target Comparison Matrix</th>
</tr>
<tr>
<td class="label">Target</td>
<td>AD Approach</td>
</tr>
<tr>
<td class="label">Amyloid-beta</td>
<td>Anti-Abeta monoclonal antibodies (lecanemab, donanemab)</td>
</tr>
<tr>
<td class="label">Tau protein</td>
<td>Anti-tau immunotherapies, kinase inhibitors</td>
</tr>
<tr>
<td class="label">alpha-Synuclein</td>
<td>N/A</td>
</tr>
<tr>
<td class="label">TDP-43</td>
<td>N/A</td>
</tr>
<tr>
<td class="label">Target</td>
<td>AD Drug Class</td>
</tr>
<tr>
<td class="label">Dopamine</td>
<td>Not applicable</td>
</tr>
<tr>
<td class="label">Dopamine receptors</td>
<td>Not applicable</td>
</tr>
<tr>
<td class="label">Cholinergic</td>
<td>Cholinesterase inhibitors</td>
</tr>
<tr>
<td class="label">Glutamate</td>
<td>NMDA antagonist</td>
</tr>
<tr>
<td class="label">Adenosine</td>
<td>Not applicable</td>
</tr>
<tr>
<td class="label">Serotonin</td>
<td>SSRIs</td>
</tr>
<tr>
<td class="label">Gene Target</td>
<td>AD Approach</td>
</tr>
<tr>
<td class="label">APP</td>
<td>ASO targeting APP</td>
</tr>
<tr>
<td class="label">SNCA</td>
<td>N/A</td>
</tr>
<tr>
<td class="label">GBA</td>
<td>N/A</td>
</tr>
<tr>
<td class="label">LRRK2</td>
<td>N/A</td>
</tr>
<tr>
<td class="label">BDNF</td>
<td>AAV-BDNF</td>
</tr>
<tr>
<td class="label">Mechanism</td>
<td>AD Targets</td>
</tr>
<tr>
<td class="label">Neuroinflammation</td>
<td>Anti-inflammatory drugs, GLP-1 agonists</td>
</tr>
<tr>
<td class="label">Oxidative stress</td>
<td>Antioxidants</td>
</tr>
<tr>
<td class="label">Mitochondrial dysfunction</td>
<td>GLP-1, mitochondria-targeted</td>
</tr>
<tr>
<td class="label">Protein homeostasis</td>
<td>Proteostasis modulators</td>
</tr>
<tr>
<td class="label">Metal homeostasis</td>
<td>Metal chelators</td>
</tr>
<tr>
<td class="label">Target Class</td>
<td>AD Candidates</td>
</tr>
<tr>
<td class="label">GLP-1 receptor</td>
<td>Semaglutide, liraglutide</td>
</tr>
<tr>
<td class="label">Sigma-1 receptor</td>
<td>Anavex 2-73</td>
</tr>
<tr>
<td class="label">CB1/CB2 cannabis</td>
<td>Nabilone</td>
</tr>
<tr>
<td class="label">TRPV1 capsaicin</td>
<td>Not in AD</td>
</tr>
<tr>
<td class="label">5-HT6 receptor</td>
<td>Idalopirdine</td>
</tr>
<tr>
<td class="label">Priority</td>
<td>AD Targets</td>
</tr>
<tr>
<td class="label">P0</td>
<td>Abeta, Tau</td>
</tr>
<tr>
<td class="label">P1</td>
<td>Neuroinflammation</td>
</tr>
<tr>
<td class="label">P2</td>
<td>Synaptic function</td>
</tr>
<tr>
<td class="label">P3</td>
<td>Metabolic support</td>
</tr>
</table>

This page provides a comprehensive comparison of therapeutic targets across Alzheimer's Disease (AD) and Parkinson's Disease (PD), highlighting common mechanisms, disease-specific approaches, and clinical development status.

Target Categories

1. Protein Aggregation Targets

2. Neurotransmitter-Based Therapies

3. Gene Therapy Approaches

4. Immunotherapy Approaches

Alzheimer's Disease

Anti-amyloid antibodies: Lecanemab, donanemab, aducanumab
Anti-tau vaccines: ACI-35, BVRL-001
Mechanism: Clear Aβ plaques, reduce tau tangles

Parkinson's Disease

Anti-α-synuclein antibodies: Cinpanemab, prasinezumab
Vaccines: PD01A, PD03A
Mechanism: Clear Lewy bodies, prevent propagation

5. Neuroprotection and Disease Modification

6. Receptor and Channel Targets

Clinical Trial Comparison

Alzheimer's Disease Pipeline (2024)

Phase 3: 15+ candidates
Phase 2: 50+ candidates
Disease modification: 8 candidates
Symptomatic: 7 candidates
Biomarker-driven: Most programs

Parkinson's Disease Pipeline (2024)

Phase 3: 10+ candidates
Phase 2: 40+ candidates
Disease modification: 6 candidates
Gene therapy: 5 programs
Cell therapy: 3 programs

Shared Therapeutic Strategies

Disease-Modifying Approaches

Protein clearance: Immunotherapies targeting misfolded proteins

Neuroinflammation: Microglial modulation, NLRP3 inhibitors

Synaptic protection: BDNF signaling, synaptic vesicle modulators

Metabolic support: Mitochondrial function, bioenergetics

Symptomatic Relief

Cognitive enhancement: Cholinesterase inhibitors, glutamatergic modulators

Motor symptoms: Dopaminergic, adenosine antagonism

Non-motor symptoms: Sleep, mood, autonomic

Target Prioritization Matrix

Cross-Disease Therapeutic Opportunities

High Potential

GLP-1 agonists: Active in both AD and PD trials

TREM2 modulators: Microglial targeting in AD, potential in PD

Autophagy enhancers: Protein clearance in both

NLRP3 inhibitors: Neuroinflammation in both

Medium Potential

Antioxidants: Mitochondrial protection

Metal chelators: Metal dysregulation

Cell therapy: Stem cell approaches

Low Potential (Disease-Specific)

APP-targeted: AD only

Dopaminergic: PD only

Tau vaccines: AD only

References

[Cummings et al., Alzheimer's disease drug development pipeline (2024)](https://doi.org/10.1002/alz.13858)

[Pagano et al., Parkinson's disease drug pipeline (2024)](https://doi.org/10.1038/s41573-024-00936-1)

[Knight et al., Gene therapy for neurodegenerative diseases (2024)](https://doi.org/10.1038/s41582-024-00856-1)

[Therapeutic Targets Overview](/therapeutics/therapeutic-targets)
[Immunotherapy Comparison](/therapeutics/immunotherapy-comparison)
[Antibody Comparison Matrix](/therapeutics/antibody-comparison-matrix)
[Combination Therapy Matrix](/therapeutics/ad-combination-therapy-matrix)
[Alzheimer's Disease](/diseases/alzheimers-disease)
[Parkinson's Disease](/diseases/parkinsons-disease)

Related Hypotheses

From the [SciDEX Exchange](/exchange) — scored by multi-agent debate

[Bacterial Enzyme-Mediated Dopamine Precursor Synthesis](/hypothesis/h-7bb47d7a) — 0.44 · Target: TH, AADC
[Glial Glycocalyx Remodeling Therapy](/hypothesis/h-c35493aa) — 0.58 · Target: HSPG2
[TREM2-mediated microglial tau clearance enhancement](/hypothesis/h-b234254c) — 0.55 · Target: TREM2
[Microbial Inflammasome Priming Prevention](/hypothesis/h-e7e1f943) — 0.76 · Target: NLRP3, CASP1, IL1B, PYCARD
[Hippocampal CA3-CA1 circuit rescue via neurogenesis and synaptic preservation](/hypothesis/h-856feb98) — 0.73 · Target: BDNF
[Vagal Afferent Microbial Signal Modulation](/hypothesis/h-ee1df336) — 0.71 · Target: GLP1R, BDNF
[Smartphone-Detected Motor Variability Correction](/hypothesis/h-072b2f5d) — 0.63 · Target: DRD2/SNCA
[TREM2 Conformational Stabilizers for Synaptic Discrimination](/hypothesis/h-044ee057) — 0.58 · Target: TREM2

Related Analyses:

[4R-tau strain-specific spreading patterns in PSP vs CBD](/analysis/SDA-2026-04-01-gap-005) 🔄
[Microglia-astrocyte crosstalk amplification loops in neurodegeneration](/analysis/SDA-2026-04-01-gap-009) 🔄
[Digital biomarkers and AI-driven early detection of neurodegeneration](/analysis/SDA-2026-04-01-gap-012) 🔄
[What are the mechanisms by which gut microbiome dysbiosis influences Parkinson's disease pathogenesi](/analysis/SDA-2026-04-01-gap-20260401-225155) 🔄
[Synaptic pruning by microglia in early AD](/analysis/SDA-2026-04-01-gap-v2-691b42f1) 🔄

📖 View canonical wiki page →

Related Entities

therapeutics-ad-pd-target-comparison-matrix

▸Metadataorigin_type: v1_polymorphic_backfill

slug	therapeutics-ad-pd-target-comparison-matrix
kg_node_id	None
entity_type	therapeutic
origin_type	v1_polymorphic_backfill
source_table	wiki_pages
wiki_page_id	wp-0ddd776f7a45
__merged_from	{'merged_at': '2026-05-13', 'unprefixed_id': 'therapeutics-ad-pd-target-comparison-matrix'}
_schema_version	1

📊 Evidence Profile Foundational

Evidence Balance

+0%

Certainty

100%

Debates

Incoming

Outgoing

0 supporting 0 contradicting 0 neutral

View full evidence profile →

🌍 Provenance Graph 1 nodes, 0 edges

No provenance edges found

This artifact has no version history yet.

Linked Artifacts (117)

mentions🔬Can speech, gait, retinal imaging, sleep, and smartphone dat100%

mentions🔬PSP and CBD both involve 4R-tau but produce distinct neuropa100%

mentions🔬Analysis question not specified100%

mentions🔬Microglia activate astrocytes via IL-1alpha/TNF/C1q, and rea100%

mentions🔬Synaptic pruning by microglia in early AD100%

mentions🧪Bacterial Enzyme-Mediated Dopamine Precursor Synthesis90%

mentions🧪TREM2-mediated microglial tau clearance enhancement70%

mentions🧪Glial Glycocalyx Remodeling Therapy70%

mentions🧪Microbial Inflammasome Priming Prevention69%

mentions🧪Hippocampal CA3-CA1 circuit rescue via neurogenesis and syna69%

mentions🧪Vagal Afferent Microbial Signal Modulation68%

mentions🧪Smartphone-Detected Motor Variability Correction66%

mentions🧪TREM2 Conformational Stabilizers for Synaptic Discrimination65%

mentions🧪Microbial Metabolite-Mediated α-Synuclein Disaggregation65%

mentions🧪Enteric Nervous System Prion-Like Propagation Blockade64%

mentions🧪Vocal Cord Neuroplasticity Stimulation63%

mentions🧫Leukocyte gene expression analysis in COVID-19 patients50%

mentions🧪Designer TRAK1-KIF5 fusion proteins accelerate therapeutic m50%

mentions🧪Cell-Type Specific TREM2 Upregulation in DAM Microglia50%

mentions🧪TREM2-Mediated Selective Aggregate Clearance Pathway50%

mentions🧫Microbiome-Gut Barrier Signatures in ALS — Experiment Design50%

mentions🧫Alpha-Synuclein Aggregation Triggers — Sporadic PD Initiatio50%

mentions🧪Matrix Stiffness Normalization via Targeted Lysyl Oxidase In50%

mentions🧫TREM2 Agonist Therapy for Parkinson's Disease — Experim50%

mentions🧪APOE-TREM2 Interaction Modulation50%

mentions🧫Microglial TREM2 Agonist In Vivo Efficacy50%

mentions🧪Glycosaminoglycan Template Disruption Approach50%

mentions🧫tACS Connectivity Trial in Early Alzheimer's50%

mentions🧪Extracellular Matrix Stiffness Modulation50%

mentions🧪TREM2-Dependent Microglial Senescence Transition50%

mentions🧫TREM2 Function in Alzheimer's Disease — From Risk Varia50%

mentions🧫RBG treatment in ApoE-/- atherosclerosis mouse model50%

see_also📖Galectin-3 Mechanism in Neurodegeneration45%

see_also📖Senescent Cell Clearance in Neurodegeneration45%

see_also📖Transdiagnostic Proteomic Changes in Neurodegeneration45%

see_also📖COVID-19 Neurodegeneration Mechanism45%

see_also📖Microglial Priming Pathway in Neurodegeneration45%

see_also📖Retinal Degeneration Pathway in Neurodegeneration45%

see_also📖Lipid Metabolism Dysregulation in Neurodegeneration45%

see_also📖Axon Guidance Pathways in Neurodegeneration45%

see_also📖HMGB1 Signaling in Neurodegeneration45%

see_also📖Sex Differences in Neurodegeneration45%

see_also📖Dystrophic Neurites in Neurodegeneration45%

see_also📖Transdiagnostic Proteomic Changes in Neurodegeneration45%

see_also📖Down Syndrome Neurodegeneration Pathway45%

see_also📖gp130/IL-6 Family Cytokine Signaling in Neurodegeneration45%

see_also📖Endosomal-Lysosomal Pathway in Neurodegeneration45%

see_also📖Therapeutic Targets in Neurodegeneration45%

see_also📖IL-1 Signaling Pathway in Neurodegeneration45%

see_also📖Antibody Therapy in Neurodegeneration45%

see_also📖Convergent Pathways in Neurodegeneration45%

mentions🧫Dexamethasone treatment study in α-synuclein mice44%

mentions🧫NLRP3 Inflammasome Validation Study in Parkinson's Dise44%

mentions🧫TLR expression in α-synuclein overexpressing mice44%

mentions🧫Longitudinal TLR2 reporter gene study in α-synuclein mice44%

mentions🔬How does metabolic reprogramming (glucose metabolism shifts,40%

mentions🔬What are the mechanisms underlying tdp-43 phase separation t40%

mentions🔬Is disrupted sleep a cause or consequence of neurodegenerati40%

mentions🔬What are the mechanisms underlying blood-brain barrier trans40%

mentions🔬What are the mechanisms underlying apoe4 structural biology 40%

mentions🔬The disease-associated microglia (DAM) phenotype involves TR40%

mentions🔬Astrocytes adopt A1 (neurotoxic) and A2 (neuroprotective) ph40%

mentions🔬TDP-43 undergoes liquid-liquid phase separation that becomes40%

mentions🔬Multiple NDDs converge on autophagy-lysosome dysfunction. Ar40%

mentions🔬What cell types are most vulnerable in Alzheimer's Dise40%

mentions🔬What are the mechanisms by which tau pathology spreads throu40%

mentions🔬Analyze circuit-level changes in neurodegeneration using All40%

mentions🔬What are the most promising therapeutic strategies for targe40%

Reference URLs

Canonical (singular)/artifact/wiki-therapeutics-ad-pd-target-comparison-matrixcanonical

Canonical (plural, REST)/artifacts/wiki-therapeutics-ad-pd-target-comparison-matrixalias

API (JSON)/api/artifacts/wiki-therapeutics-ad-pd-target-comparison-matrixapi

Citation — BibTeX/artifacts/wiki-therapeutics-ad-pd-target-comparison-matrix/cite?fmt=bibtexexport

Citation — RIS/artifacts/wiki-therapeutics-ad-pd-target-comparison-matrix/cite?fmt=risexport

Citation — CSL-JSON/artifacts/wiki-therapeutics-ad-pd-target-comparison-matrix/cite?fmt=cslexport

Embed this artifact

Use ?embed=1 to load the artifact without SciDEX chrome — suitable for iframing into wiki pages or external sites.

HTML iframe

<iframe src="http://scidex.ai/artifact/wiki-therapeutics-ad-pd-target-comparison-matrix?embed=1" width="100%" height="600" style="border:0;border-radius:8px"></iframe>

Markdown link

[AD/PD Therapeutic Target Comparison Matrix](http://scidex.ai/artifact/wiki-therapeutics-ad-pd-target-comparison-matrix)

Direct URL

http://scidex.ai/artifact/wiki-therapeutics-ad-pd-target-comparison-matrix

Preview

🔄 Adjacent Artifacts Recommended based on your interests

💬 Discussion

Loading comments...

Public annotations (0)Annotate on Hypothes.is →

No public annotations yet.

📗 Cite This Artifact

AD/PD Therapeutic Target Comparison Matrix

AD/PD Therapeutic Target Comparison Matrix

Overview

AD/PD Therapeutic Target Comparison Matrix

Overview

Target Categories

1. Protein Aggregation Targets

2. Neurotransmitter-Based Therapies

3. Gene Therapy Approaches

4. Immunotherapy Approaches

Alzheimer's Disease

Parkinson's Disease

5. Neuroprotection and Disease Modification

6. Receptor and Channel Targets

Clinical Trial Comparison

Alzheimer's Disease Pipeline (2024)

Parkinson's Disease Pipeline (2024)

Shared Therapeutic Strategies

Disease-Modifying Approaches

Symptomatic Relief

Target Prioritization Matrix

Cross-Disease Therapeutic Opportunities

High Potential

Medium Potential

Low Potential (Disease-Specific)

References

Related Pages

Related Hypotheses

💬 Discussion